Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Patients who are known to have human immunodeficiency virus (HIV) or are on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are INELIGIBLE
Human immunodeficiency virus (HIV)-positive subjects on combination antiretroviral therapy are ineligible
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies); HIV-positive participants on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible due to potential drug-drug interactions with PT2385
Human immunodeficiency virus (HIV)-positive participants on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive participants on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV) positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive participants on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy
Known human immunodeficiency virus (HIV)-positive on combination antiretroviral therapy
Known HIV-positive patients on combination antiretroviral therapy.
Human immunodeficiency virus (HIV)-positive and on combination antiretroviral therapy
Human immunodeficiency virus (HIV)-positive participants on combination antiretroviral therapy are ineligible
Known human immunodeficiency virus (HIV)-positive participants on combination antiretroviral therapy are ineligible
A known history of human immunodeficiency virus (HIV) seropositivity; HIV-positive patients on combination antiretroviral therapy are ineligible
Patients may not have known human immunodeficiency virus (HIV) infection; HIV-positive patients on combination antiretroviral therapy are ineligible
Patients known to be human immunodeficiency virus (HIV) positive and currently receiving antiretroviral therapy
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Patients with active human immunodeficiency virus (HIV) or hepatitis C; (HIV-positive patients on combination antiretroviral therapy or hepatitis C-positive patients on antiviral therapy are ineligible)
Patients with known prior human immunodeficiency virus (HIV)-positive status on combination antiretroviral therapy are ineligible; known prior HIV-positive patients with cluster of differentiation (CD)4+ =< 500/mm^3 are ineligible (HIV testing is not required as part of this study)
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV) positive patients on antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients receiving combination antiretroviral therapy are excluded from the study
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions vemurafenib and cobimetinib
COHORT 1: HORMONE RECEPTOR POSITIVE BREAST CANCER: Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
COHORT 3: ENDOMETRIAL CANCER: HIV-positive patients on combination antiretroviral therapy are ineligible
Patients with human immunodeficiency virus (HIV) on antiretroviral therapy are ineligible
Known human immunodeficiency virus (HIV)-positive test on combination antiretroviral therapy
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with meclizine.
Human deficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV) seropositive patients with acceptable organ function who meet the patient selection criteria, and who are not on combination antiretroviral therapy, and whose absolute CD4+ count is >= 400 cells per cubic millimeter of blood, will be eligible; however, HIV positive patients on combination antiretroviral therapy will be ineligible, because of the potential for pharmacokinetic interactions with cabozantinib
Human immunodeficiency virus (HIV)-positive participants on combination antiretroviral therapy are ineligible
Known human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Known human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy
Patients with known human immunodeficiency virus (HIV) on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV) positive patients with CD4 counts below 500 OR who are not on a stable dose of antiretroviral therapy (for at least 1 month prior to registration) are ineligible
Known human immunodeficiency virus (HIV)-positive patients who are on combination antiretroviral therapy; (this is because of the potential for pharmacokinetic interactions with denosumab)
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are eligible provided they have stable CD4 counts above 250
Patients on combination antiretroviral therapy, i.e. those who are human immunodeficiency virus (HIV)-positive, are ineligible; HIV testing is not required, but patients must not be known to be HIV-positive
Patients who are human immunodeficiency virus (HIV)-positive on combination antiretroviral therapy
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients with uncontrolled HIV despite combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Patients on combination antiretroviral therapy for the treatment of human immunodeficiency virus (HIV) are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy
PHASE I AND II SCLC AND UROTHELIAL CARCINOMA EXPANSION COHORT: Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
mCRPC EXPANSION COHORT: HIV-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Known human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive subjects on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Patients who are known to be human immunodeficiency positive (HIV)-positive and are on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
HIV-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with vandetanib/metformin
Human immunodeficiency virus (HIV)-positive subjects on combination antiretroviral therapy are ineligible
Subjects known to be human immunodeficiency virus (HIV)-positive, including those on combination antiretroviral therapy, are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Patients with a known human immunodeficiency virus (HIV)-positive test on combination antiretroviral therapy are ineligible for the initial first-in-man trial
The subject is known to be positive for the human immunodeficiency virus (HIV) and is receiving antiretroviral therapies; subjects known to be HIV-positive who do not require antiretroviral therapy will be eligible if they meet other entry criteria
HIV-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Patients known to be human immunodeficiency virus (HIV)-positive patients and on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral treatment are ineligible
History of human immunodeficiency virus (HIV) or HIV-positive patients on combination antiretroviral therapy are ineligible
HIV-positive patients on combination antiretroviral therapy are ineligible because of unknown potential for interactions with cenersen.
Human immunodeficiency virus (HIV) positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with lenvatinib
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients receiving combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Known human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Known human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
TUMOR BIOPSY SEQUENCING: Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
TREATMENT: HIV-positive patients on combination antiretroviral therapy are ineligible
Known human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Immunocompromised patients, e.g., patients who are known to be serologically positive for human immunodeficiency virus (HIV); HIV-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency (HIV)-positive participants on combination antiretroviral therapy are ineligible
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies); HIV-positive participants on combination antiretroviral therapy are ineligible
Known human immunodeficiency virus (HIV) or other history of immunodeficiency disorder; HIV-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
HIV-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Known human immunodeficiency virus (HIV) or other history of immunodeficiency disorder \r\n* NOTE: HIV-positive patients taking combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients receiving combination antiretroviral therapy are excluded from the study
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are not eligible
Human immunodeficiency virus (HIV) positive patients who are on combination antiretroviral therapy
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Known human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy
Known human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Known human immunodeficiency virus (HIV)-positive subjects on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are eligible; unless the patientâ€™s CD4 count is below the institutional lower limit of normal
Known human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Patients who are known to have human immunodeficiency virus (HIV) or are on combination antiretroviral therapy are ineligible
Subjects known to be human immunodeficiency virus (HIV)-positive, including those on combination antiretroviral therapy, are ineligible
Patients who are human immunodeficiency virus (HIV) positive must be willing to comply with effective antiretroviral therapy
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive participants on combination antiretroviral therapy are ineligible
HIV-positive participants on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive participants on CYP3A4 modulating antiretroviral therapy are ineligible
Patients on combination antiretroviral therapy, i.e. those who are human immunodeficiency virus (HIV)-positive, are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; this applies only to patients who have a documented history of HIV and HIV testing is not otherwise required
Human immunodeficiency virus (HIV)-positive participants on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Confirmed human immunodeficiency virus (HIV) positive whether or not on antiretroviral therapy
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
HIV-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Patients on combination antiretroviral therapy, i.e. those who are human immunodeficiency virus (HIV)-positive, are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; Note: patients not on antiretroviral therapies are eligible for this study
Human immunodeficiency virus (HIV)-positive patients or those on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive subjects on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients receiving combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
HIV-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; HIV- positive patients who are not on combination antiretroviral therapy (cART) and have CD4 counts > 500 are eligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Patients with human immunodeficiency virus (HIV) whom are not receiving antiretroviral therapy
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients receiving combination antiretroviral therapy are ineligible
Known human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Known human immunodeficiency virus (HIV)-positive patients receiving combination antiretroviral therapy are ineligible; HIV testing is not required for study enrollment and optional
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy; NOTE: HIV-positive patients on combination antiretroviral therapy are ineligible; in addition, these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy
Patients that are human immunodeficiency virus (HIV)-positive on combination antiretroviral therapy
Patient is human immunodeficiency virus (HIV)-positive and is receiving combination antiretroviral therapy
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
HIV-positive patients on combination antiretroviral therapy.
HIV-positive patients on combination antiretroviral therapy are ineligible
Subjects who are human immunodeficiency virus (HIV)-positive on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
HIV-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Known human immunodeficiency virus (HIV) positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive participants on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; this applies only to patients who have a documented history of HIV; HIV testing is not otherwise required
Human immunodeficiency virus (HIV)-positive subjects on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Patient must not be known to be human immunodeficiency virus (HIV)-positive on combination antiretroviral therapies
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
HIV-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive participants on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive participants on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive participants on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with ferumoxytol
Human immunodeficiency virus (HIV)-positive subjects on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with ferumoxytol
Human immunodeficiency virus (HIV)-positive participants on combination antiretroviral therapy are ineligible
Patient must not be known to be human immunodeficiency virus (HIV)-positive on combination antiretroviral therapy
Human immunodeficiency virus (HIV)-positive participants on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive subjects on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive subjects on combination antiretroviral therapy are ineligible
Known human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are ineligible; HIV testing is not required for inclusion in this study
Known history of human immunodeficiency virus (HIV); testing is not required in the absence of prior documentation or known history; HIV-positive individuals on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive individuals are ineligible
ENROLLMENT TO THE DOSE ESCALATION, EXPANSION AND PART II: Known human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive individuals on combination anti-retroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are ineligible
Individuals who are known to be human immunodeficiency virus (HIV)-positive on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are ineligible
Known human immunodeficiency virus (HIV)-positive individuals are ineligible
Human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are ineligible
HIV positive individuals on combination antiretroviral therapy are ineligible
Participants known to be human immunodeficiency virus (HIV)-positive are excluded (Note: HIV testing is not required prior to enrollment). HIV-positive individuals on combination antiretroviral therapy are ineligible
Known human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are eligible so long as they meet all other criteria; known HIV-positive individuals who are not on combination antiretroviral therapy are not eligible
Known human immunodeficiency virus (HIV)-positive individuals are ineligible
Participants known to be human immunodeficiency virus (HIV)-positive are excluded (note: HIV testing is not required prior to enrollment); HIV-positive individuals on combination antiretroviral therapy are ineligible
Known human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are ineligible
Known human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are ineligible
Negative human immunodeficiency virus (HIV) blood test within 21 days of study entry; HIV-positive individuals on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are ineligible; HIV testing is required only for patients deemed to be high-risk
Human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are ineligible
HIV-positive individuals on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are ineligible
PHASE II: Human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are eligible so long as they meet all other criteria; HIV-positive individuals who are not on combination antiretroviral therapy are not eligible
Human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are ineligible
HIV-positive individuals on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are eligible so long as they meet all other criteria; HIV-positive individuals who are not on combination antiretroviral therapy are not eligible
Human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are eligible for enrollment and will be monitored closely for potential pharmacokinetic interactions with neratinib
Human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are ineligible
HIV-positive individuals on combination antiretroviral therapy are ineligible
EXPANSION COHORT ONLY: HIV-positive individuals on combination antiretroviral therapy are ineligible
Known human immunodeficiency virus (HIV)-positive individuals are ineligible
Known HIV-positive individuals on combination antiretroviral therapy.
Human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are ineligible; HIV-positive individuals on highly active antiretroviral therapy (HAART) will be considered eligible if they have demonstrated good compliance and have a cluster of differentiation (CD)4 count > 500
Human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are ineligible
HIV-positive individuals on combination antiretroviral therapy.
HIV-positive individuals on combination antiretroviral therapy.
HIV-positive individuals on combination antiretroviral therapy.
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; patients must also have a CD4 count > 350 cells/mm^3 with an undetectable viral load
Patients positive for human immunodeficiency virus (HIV) are allowed on study, but HIV-positive patients must have:\r\n* A stable regimen of highly active anti-retroviral therapy (HAART)\r\n* No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections\r\n* A CD4 count above 250 cells/mcL and an undetectable HIV viral load on standard polymerase chain reaction (PCR)-based tests
Human immunodeficiency virus (HIV)-patients positive for human immunodeficiency virus (HIV) are NOT excluded from this study, however HIV-positive patients must meet the following criteria:\r\n* A stable regimen of highly active anti-retroviral therapy (HAART)\r\n* No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections\r\n* A CD4 count above 250 cells/mcL and an undetectable HIV viral load on standard polymerase chain reaction (PCR)-based test
Patients who are human immunodeficiency virus (HIV) positive may participate IF they meet the following eligibility requirements:\r\n* They must be stable on their anti-retroviral regimen, and they must be healthy from an HIV perspective\r\n* They must have an undetectable viral load\r\n* They must have a CD4 count of greater than 250 cells/mcL \r\n* They must not be receiving prophylactic therapy for an opportunistic infection
Patients who are human immunodeficiency virus (HIV)-positive are eligible if: \r\n* CD4+ cell count greater or equal to 250 cells/mm^3\r\n* If patient is on antiretroviral therapy, there must be minimal interactions or overlapping toxicity of the antiretroviral therapy with the experimental cancer treatment; for experimental cancer therapeutics with CYP3A/4 interactions, protease inhibitor therapy is disallowed; suggested regimens to replace protease inhibitor therapy include dolutegravir given with tenofovir/emtricitabine; raltegravir given with tenofovir and emtricitabine; once daily combinations that use pharmacologic boosters may not be used\r\n* No history of non-malignancy acquired immune deficiency syndrome (AIDS)-defining conditions other than historical low CD4+ cell counts\r\n* Probable long-term survival with HIV if cancer were not present
Patients with known human immunodeficiency virus (HIV) may be eligible providing they meet the following additional criteria:\r\n* Cluster of differentiation (CD)4 cells >= 500/uL\r\n* Serum HIV viral load of < 25,000 IU/ml\r\n* No current antiretroviral therapy\r\n** Tests must be obtained within 28 days prior to registration; patients who are HIV positive (+) and do not meet all of these criteria are not eligible for this study (HIV/hepatitis testing are not required for patients without known infection)
Patients positive for human immunodeficiency virus (HIV) are eligible only if they meet all of the following:\r\n* A stable regimen of highly active anti-retroviral therapy (HAART)\r\n* No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections\r\n* A CD4 count above 250 cells/mcL, and an undetectable HIV viral load on standard PCR-based tests
Patients positive for human immunodeficiency virus (HIV) are NOT excluded from this study, but HIV-positive patients must have:\r\n* A stable regimen of highly active anti-retroviral therapy (HAART)\r\n* No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections\r\n* A cluster of differentiation (CD)4 count above 250 cells/mcL and an undetectable HIV viral load on standard PCR-based tests
Patients with known human immunodeficiency virus (HIV) infection are eligible if they meet all of the following criteria:\r\n* No history of acquired immune deficiency syndrome (AIDS)-related complications other than a history of low CD4+ T-cell count (< 200/mm^3) prior to initiation of combination antiretroviral therapy; on study CD4+ T-cell count may not be informative due to leukemia and should not be used as an exclusion criterion if low\r\n* Patient must be healthy on the basis of HIV disease with high likelihood of near normal life span were it not for the leukemia\r\n* Patient must have serum HIV viral load of < 200 copies/mm^3\r\n* Patient must be on combination antiretroviral therapy with minimal pharmacokinetic interactions with study therapy and minimal overlapping clinical toxicity with protocol therapy\r\n* Patient must not be receiving protease inhibitors or once daily formulations containing cobicistat, stavudine, or on regimens containing stavudine or zidovudine\r\n* It is recommended to utilize a regimen of the integrase inhibitor, dolutegravir, combined with either disoproxil fumarate/emtricitabine or dolutegravir combined with tenofovir alafenamide/emtricitabine
Patients with hepatitis B virus infection must have undetectable hepatitis B virus (HBV) on suppressive therapy and no evidence of HBV-related hepatic damage; patients with hepatitis C virus infection are eligible if complete eradication therapy has been successfully completed, and there is no detectable hepatitis C virus (HVC) or related hepatic damage; patients with known human immunodeficiency virus (HIV) infection are eligible if they meet all of the following criteria:\r\n* Patient must have no history of acquired immune deficiency syndrome (AIDS)-related complications, other than a history of low CD4+ T-cell count (< 200/mm3) prior to initiation of combination antiretroviral therapy; on study CD4+ T-cell count may not be informative due to leukemia and should not be used as an exclusion criterion if low\r\n* Patient must be healthy on the basis of HIV disease with high likelihood of near normal life span were it not for the leukemia\r\n* Patient must have serum HIV viral load of < 200 copies/mm^3\r\n* Patient must be on combination antiretroviral therapy with minimal pharmacokinetic interactions with study therapy and minimal overlapping clinical toxicity with protocol therapy; (recommend a regimen of the integrase inhibitor dolutegravir combined with either disoproxil fumarate/emtricitabine or dolutegravir combined with tenofovir alafenamide/emtricitabine)\r\n* Protease inhibitors and once daily formulations containing cobicistat are NOT allowed\r\n* Stavudine and zidovudine (AZT) are NOT allowed
Patients positive for human immunodeficiency virus (HIV) are NOT excluded from this study, but HIV-positive patients must have:\r\n* A stable regimen of highly active anti-retroviral therapy (HAART); and\r\n* No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections; and\r\n* A CD4 count above 250 cells/uL and an undetectable HIV viral load on standard PCR-based tests
Human immunodeficiency virus (HIV) positive patients are not excluded, but to enroll, must meet all of the below criteria:\r\n* HIV is sensitive to antiretroviral therapy\r\n* Must be willing to take effective antiretroviral therapy that has minimal overlapping toxicity and pharmacokinetic interactions with protocol therapy\r\n* No history of HIV-related opportunistic disease or acquired immune deficiency syndrome (AIDS)-defining conditions within past 12 months other than historic CD4+ T-cell counts below 200 cells/mm^3\r\n* Expected long-term survival if lymphoma were not present
Patients with human immunodeficiency virus (HIV) infection are eligible, provided they meet the following:\r\n* No history of acquired immunodeficiency syndrome (AIDS)-defining conditions or other HIV related illness\r\n* Cluster of differentiation (CD)4+ cells nadirs > 350/mm^3 within 28 days prior to registration\r\n* Treatment sensitive HIV and, if on anti-HIV therapy, HIV viral load < 50 copies/mm^3 within 28 days prior to registration\r\n* Note: HIV+ patients who enroll on this study and are assigned to treatment with ixazomib may need to modify their anti-retroviral therapy prior to receiving protocol therapy if they are on strong inducers or potent inhibitors of cytochrome P450 3A4
Patients known to be human immunodeficiency virus (HIV) positive are eligible if they meet the following criteria within 30 days prior to registration: stable and adequate CD4 counts (>= 350 mm^3), and serum HIV viral load of < 25,000 IU/ml; patients must be on a stable anti-viral therapy
Patients positive for human immunodeficiency virus (HIV) are eligible only if they have all of the following:\r\n* A stable regimen of highly active anti-retroviral therapy (HAART)\r\n* No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections\r\n* A CD4 count above 250 cells/mcL and an undetectable HIV viral load on standard PCR-based tests
Patients known to be positive for HIV (the human immunodeficiency virus) may be eligible, providing they meet the following additional criteria within 28 days prior to registration:\r\n* No history of acquired immune deficiency syndrome (AIDS)-defining conditions\r\n* CD4 cells > 350 cells/mm^3\r\n* If on antiretroviral agents, must not include zidovudine or stavudine\r\n* Viral load =< 50 copies HIV messenger ribonucleic acid (mRNA)/mm^3 if on combination antiretroviral therapy (cART) or =< 25,000 copies HIV mRNA/mm^3 if not on cART\r\n* Highly active antiretroviral therapy (HAART) regimens are acceptable providing they have only weak P450A4 interactions
No history of the following:\r\n* Autoimmunity requiring systemic immunosuppression within 2 years\r\n* Patients known to be human immunodeficiency virus (HIV) positive are eligible if they meet the following:\r\n** CD4 counts >= 350 mm^3\r\n** Serum HIV viral load of < 25,000 IU/ml
Patients positive for human immunodeficiency virus (HIV) are NOT excluded from this study, but HIV-positive patients must have:\r\n* A stable regimen of highly active anti-retroviral therapy (HAART)\r\n* No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections\r\n* A CD4 count above 250 cells/mcL and an undetectable HIV viral load on standard polymerase chain reaction (PCR)-based test
Patients who are known to be human immunodeficiency virus positive (HIV+) are eligible providing they meet all of the following additional criteria within 28 days prior to registration:\r\n* CD4+ cells >= 350/mm^3 (nadir)\r\n* Viral load of < 50 copies HIV messenger ribonucleic acid (mRNA)/mm^3 if on combination antiretroviral therapy (cART) or < 25,000 copies HIV mRNA if not on cART\r\n* No zidovudine or stavudine as part of cART\r\nPatients who are HIV+ and do not meet all of these criteria are not eligible for this study
ELIGIBILITY CRITERIA - PHASE I (ARMS A, B, C): Patient cannot have poorly controlled human immunodeficiency virus (HIV), or CD4 < 400; HIV positive patients are allowed on this study if they have a CD4 count >= 400, and are on a stable antiviral regimen
Patients with known active hepatitis (i.e., hepatitis B or C) or human immunodeficiency virus (HIV) with detectable viral load (history of HIV with undetectable viral load is allowed)
Patients who have previously tested positive for human immunodeficiency virus (HIV) are NOT excluded from this study (please note: testing of all patients wishing to enroll is NOT required), but HIV-positive patients must have:\r\n* A stable regimen of highly active anti-retroviral therapy (HAART)\r\n* No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections\r\n* A CD4 count above 250 cells/mcL and an undetectable HIV viral load on standard PCR-based tests
Must be on a multi-drug anti-HIV regimen (excluding zidovudine [AZT, ZDV, Retrovir], or agents containing zidovudine [e.g., Combivir and Trizivir], and efavirenz [Sustiva], or agents containing efavirenz [e.g., Atripla]), and have an HIV-1 viral load < 50 copies/mL by reverse transcriptase-polymerase chain reaction (RT-PCR) within 6 months prior to study enrollment; for patients who have had negative viral loads in the past 6 months and no known HIV viral load (VL) > 500 copies/mL within the past 6 months, minor fluctuations of viral load (isolated escalations up to 500 copies/mL) are acceptable; the participant's history of negative viral loads may be documented with recent laboratory results and/or a record from the participant's HIV care provider; participants on zidovudine [AZT, ZDV, Retrovir; including Combivir and Trizivir] and efavirenz [Sustiva; including Atripla] must switch to an alternative regimen without anticipated drug-drug interactions or myelosuppressive properties based on known viral resistance patterns and/or ART history, such as raltegravir and Truvada (emtricitabine and tenofovir) at least two weeks prior to the transplant
Patients with human immunodeficiency virus (HIV) infection may be eligible provided they meet the following:\r\n* No history of acquired immunodeficiency syndrome (AIDS)-defining conditions or other HIV related illness\r\n* Cluster of differentiation (CD)4+ cells nadirs > 350/mm^3\r\n* Treatment sensitive HIV and, if on anti-HIV therapy, HIV viral load < 50 copies/mm^3; please note: HIV+ patients who enroll on this study may need to modify their anti-retroviral therapy prior to receiving protocol therapy if they are on strong inducers or potent inhibitors of cytochrome P450 3A4; adverse events in HIV+ patients will be reported separately
Positive test for the human immunodeficiency virus (HIV) unless undetectable viral load within 3 months of enrollment (HIV ribonucleic acid [RNA] less than 48 copies/mL) and on highly active antiretroviral therapy (HAART) therapy
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; it is not necessary to conduct HIV testing at screening; patients who are HIV-positive with undetectable viral loads, not on interacting antiretroviral therapy, and have CD4 counts above 300/mm^3 may be eligible after discussion with the principal investigator
Patients who are known to be human immunodeficiency virus (HIV)-positive at registration are eligible at the time of registration as long as:\r\n* CD4+ cell count >= 250 cells/mm^3\r\n* If patient is on antiretroviral therapy, there must be minimal interactions or overlapping toxicity of the antiretroviral therapy with the study drugs; once daily combinations that use pharmacologic boosters may not be used\r\n* No history of non-malignancy acquired immune deficiency syndrome (AIDS)-defining conditions other than historical low CD4+ cell counts
Patients positive for human immunodeficiency virus (HIV) are allowed on study, but HIV-positive patients must have:\r\n* A stable regimen of highly active anti-retroviral therapy (HAART)\r\n* No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections\r\n* A CD4 count above 250 cells/mcL and an undetectable HIV viral load on standard polymerase chain reaction (PCR)-based tests
Human immunodeficiency virus (HIV) positive subjects with 1 or more of the following:\r\n* Not receiving highly active antiretroviral therapy\r\n* A change in antiretroviral therapy within 6 months of the start of screening (except if, after consultation with the sponsor on exclusion criterion below; a change is made to avoid a potential drug-drug interaction with the study drug)\r\n* Receiving antiretroviral therapy that may interfere with the study drug (consult the sponsor for review of medication prior to enrollment)\r\n* CD4 count < 350 at screening\r\n* An acquired immunodeficiency syndrome-defining opportunistic infection within 6 months of the start of screening
Human immunodeficiency virus (HIV)-positive patients are eligible provided the following criteria are met: CD4 count > 350/mm^3, an undetectable viral load, and not receiving prophylaxis antibiotics
Human immunodeficiency virus (HIV)-positive patients with well-controlled disease, as determined by CD4 count and viral load, who are on antiretroviral therapy that does not contain a strong inducer or inhibitor of CYP3A4 (e.g. regimens containing ritonavir, cobicistat, efavirenz or etravirine) are allowed on trial; HIV-positive patients on combination antiretroviral therapy with strong inducers or inhibitors of CYP3A4 are ineligible; patients with poorly controlled HIV are not eligible
Human immunodeficiency virus (HIV)+ patients are eligible for the trial provided they meet the other study criteria in addition to the following:\r\n* CD4+ T-cells >= 250/mm^3\r\n* HIV sensitive to antiretroviral therapy\r\n* Zidovudine not allowed\r\n* Long term survival anticipated on the basis of HIV alone were it not for the lymphoma\r\n* No concurrent acquired immunodeficiency syndrome (AIDS)-defining illness other than the lymphoma
CD4 count < 200 cells/ml and detectable viral load within the least 3 months (HIV infected participants
Patients who are human immunodeficiency virus (HIV) positive may participate IF they meet the following eligibility requirements:\r\n* They must be stable on their anti-retroviral regimen, and they must be healthy from an HIV perspective\r\n* They must have a CD4 count of greater than 250 cells/mcL\r\n* They must not be receiving prophylactic therapy for an opportunistic infection
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; HIV-positive patients who are not on highly active anti-retroviral therapy (HAART) and have CD4 counts > 500 will be considered on an individual basis
Known infection with human immunodeficiency virus (HIV); hepatitis B is allowed only if viral load is undetectable and if on anti-hepatitis B therapy like entecavir; hepatitis C is allowed only if viral load is undetectable, and if the patient has received curative therapy
Patients with human immunodeficiency virus (HIV)-1 may be eligible if they meet the following conditions:\r\n* CD4 cell count > 350 cells/mm3 obtained within 90 days prior to study start.\r\n* Plasma HIV-1 ribonucleic acid (RNA) below detected limit obtained by Food and Drug Administration (FDA)-approved assays for > 2 years on combination anti-retroviral therapy (cART). \r\n* Plasma HIV-1 RNA level of less than 40 copies/mL obtained by the Abbott m2000 assay or less than 20 copies/mL by Roche Taqman version (v)2.0 assay within 90 days prior to study start.\r\n* Plasma HIV-1 RNA greater than or equal to 0.4 copies/mL by single copy assay within 120 days prior to entry.\r\n* Receiving a stable cART regimen containing at least 3 agents (not including ritonavir if less than a 200 mg total daily dose) with no change in the components of antiretroviral therapy for at least 90 days prior to study entry.
Patients serologically positive for human immunodeficiency virus (HIV), hepatitis (Hep) B, Hep C are eligible as long as the viral loads are undetectable by quantitative polymerase chain reaction (PCR); HIV positive patients must have CD4 count >= 300 cells per cubic millimeter at enrollment, be on stable antiretroviral therapy and have no reported opportunistic infections within 12 months prior to enrollment
Patients known to be human immunodeficiency virus (HIV) positive are eligible if they meet the following criteria within 30 days prior to registration: stable and adequate CD4 counts (>= 350 mm^3), and serum HIV viral load of < 25,000 IU/ml; patients may be on or off anti-viral therapy so long as they meet the CD4 count criteria
Human Immunodeficiency virus (HIV) positive patients are included if CD4+ T-cell count > 200 cells/uL; on stable antiretroviral therapy for > 1 year with HIV viral load < 200 copies/mL, and no history of opportunistic infections in > 1 year
Patients positive for human immunodeficiency virus (HIV) are NOT excluded from this study, but HIV-positive patients must have:\r\n* A stable regimen of highly active anti-retroviral therapy (HAART)\r\n* No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections\r\n* A CD4 count above 250 cells/mcL and an undetectable HIV viral load on standard PCR-based tests
Human immunodeficiency virus (HIV) infected patients are eligible provided they meet all the other eligibility criteria of the study in addition to the following: \r\n* No history of acquired immune deficiency syndrome (AIDS)-defining conditions other than lymphoma or history of CD4+ T-cells below 200/mm^3 prior to beginning combination antiretroviral therapy (cART)\r\n* After HIV diagnosis and during treatment with cART, patients should have maintained CD4+ T-cells >= 350/mm^3 prior to lymphoma diagnosis; patients who never immune reconstituted to a stable level above 350/mm^3 are not eligible\r\n* At time of study entry CD4+ T-cells must have recovered from prior lymphoma therapy to >= 250/mm^3\r\n* At the time of study entry the HIV viral load must be undetectable by standard laboratory assay \r\n* During prior lymphoma therapy, patients must not have experienced documented infections attributed to the HIV+ status\r\n* No history of non-adherence to cART and willing to adhere to cART while on study\r\n* Antiretroviral drugs with overlapping or similar toxicity profiles as study agents not allowed:\r\n** Efavirenz not allowed\r\n** Stavudine not allowed\r\n** Zidovudine not allowed\r\n* Patients must be willing to be followed at a minimum of approximately every 3 months by physician expert in HIV disease management
Human immunodeficiency virus (HIV) infected patients (if HIV positive)\r\n* HIV infected individuals are eligible provided they meet all the protocol eligibility criteria in addition to the following:\r\n** No history of acquired immune deficiency syndrome (AIDS) defining illness other than a historic CD4+ T-cell nadir < 200/mm^3\r\n** Prior to leukemia diagnosis, the HIV disease was uncomplicated as evidenced by:\r\n*** The CD4+ T-cell counts were generally in excess of 300/mm^3\r\n*** The HIV viral loads were less than 200 copies/ml if on anti-HIV therapy\r\n*** If the HIV is newly diagnosed or there is no history of using anti-HIV therapy, there are no AIDS defining conditions or other HIV-related symptoms\r\n*** Zidovudine is not allowed as part of the anti-HIV therapy
Human immunodeficiency virus (HIV) positive with detectable viral load, or anyone not on stable anti?viral (highly active antiretroviral therapy [HAART]) regimen
In order for patients with known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS) to be eligible, they must be on a stable highly active antiretroviral therapy (HAART) regimen, have CD4 counts > 350, with no detectable viral load on quantitative polymerase chain reaction (PCR)
Human immunodeficiency virus (HIV)-patients positive for human immunodeficiency virus (HIV) are NOT excluded from this study, but HIV-positive patients must have:\r\n* A stable regimen of highly active anti-retroviral therapy (HAART) that does not include strong inhibitors and strong or moderate inducers of CYP3A4\r\n* No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections\r\n* A CD4 count above 250 cells/mcL and an undetectable HIV viral load on standard polymerase chain reaction (PCR)-based test
Human immunodeficiency virus (HIV)-positive patients are eligible provided they meet all the other protocol eligibility criteria including the following:\r\n* Undetectable HIV viral load by standard clinical assay\r\n* Willing to adhere to antiretroviral therapy that has minimal overlapping toxicity or pharmacokinetic interactions with protocol therapy\r\n* CD4+ T cell counts of 200/mm^3 or greater\r\n* No acquired immunodeficiency syndrome (AIDS)-defining events other within the past 12 months\r\n* Near normal life expectancy if not for the presence of the cancer\r\nAlso, HIV-positive patients must not be on HIV medications considered to be inhibitors or inducers of CYP3A4
Human immunodeficiency virus (HIV) positive patients who are otherwise eligible for this study may be enrolled if they meet the following requirements:\r\n* Are seen in the infectious disease (ID)/HIV clinic prior to enrollment on study for the purpose of determining eligibility and for local coordination of HIV care during the peri-transplant period\r\n** Are on maximally active anti-HIV regimen to control disease as determined appropriate by the ID/HIV physicians; for the majority of patients, this will be a highly active anti-retroviral therapy (HAART)-type therapy including a protease inhibitor\r\n* CD4+ >= 50/uL\r\n* HIV ribonucleic acid (RNA) viral load =< 100,000 copies per mL on each of samples 4 weeks apart; the most recent level must be within 30 days of enrollment
Patients with human immunodeficiency virus (HIV) are eligible for the study provided they meet the other protocol criteria in addition to the following: \r\n* Undetectable HIV load by standard polymerase chain reaction (PCR) clinical assay\r\n* Absolute CD4 count of >= 200 mm^3\r\n* Willing to maintain adherence to combination antiretroviral therapy\r\n* No history of acquired immunodeficiency syndrome (AIDS) defining condition (other than lymphoma or CD4 cell count < 200 mm^3)\r\n* Likely to have near normal lifespan if not for the presence of relapsed/refractory lymphoma\r\n**Patients with evidence of hepatitis B virus (HBV) are eligible provided there is minimal hepatic injury and the patient has undetectable HBV on suppressive HBV therapy; patient must be willing to maintain adherence to HBV therapy\r\n** Patients with previously treated and eradicated hepatitis C virus (HCV) who have minimal hepatic injury are eligible
Known human immunodeficiency virus (HIV) positive (+) patients; EXCEPTION: if they meet the following additional criteria =< 28 days prior to registration:\r\n* CD4 cells >= 500/mm^3\r\n* Viral load of < 50 copies HIV messenger (m) ribonucleic acid (RNA)/mm^3 if on combination antiretroviral therapy (cART) or < 10,000 copies HIV mRNA if not on cART\r\nâ€¢ No zidovudine or stavudine as part of cART
Has an active infection requiring systemic therapy; exception HIV on antiretrovirals with negative viral load
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy may be eligible if there are no pharmacokinetic interactions with the agents used on the study, stable on chimeric antigen receptor T cell (CART) therapy and cluster of differentiation (CD)4 is > 200 and viral load is undetectable
PRIOR TO LYMPHODEPLETION: Active infection with HIV, HTLV, HCV (can be pending at the time of cell procurement; only those samples confirming lack of active infection will be used to generate transduced cells) defined as not being well controlled on therapy; patients are required to have negative HIV antibody or negative HIV viral load, negative HTLV1 and 2 antibodies, negative HCV antibody or viral load
PRIOR TO INFUSION OF ATLCAR.CD30 CELLS: Active infection with HIV, HTLV, HCV (can be pending at the time of cell procurement; only those samples confirming lack of active infection will be used to generate transduced cells) defined as not being well controlled on therapy; patients are required to have negative HIV antibody or negative HIV viral load, negative HTLV1 and 2 antibodies, negative HCV antibody or viral load
Highly active antiretroviral therapy (HAART) for HIV+ patients:\r\n* All HIV+ patients must be willing to be compliant with HAART\r\n* Group I â€“ on HAART for 1 month with stable disease; however, no minimum time restriction for patients with progressive and/or end-organ threatening disease\r\n* Group II â€“ no minimum time restriction on prior HAART, patients may be HAART naive
Patients with human immunodeficiency virus (HIV) who are not receiving cytochrome p450 inhibitors, and who have a minimum of 300+ CD4+ cells/mm^3, an undetectable viral load, and no history of acquired immunodeficiency syndrome (AIDS) indicator conditions
Patient must be willing to undergo testing for human immunodeficiency virus (HIV) if not tested within the past 6 months. If HIV+ positive, patient will be eligible if: his/ her CD4+ count ? 300/?L; his/her viral load is undetectable; he/she is currently receiving highly active antiretroviral therapy (HAART).
Human immunodeficiency virus (HIV) infection, unless receiving effective antiretroviral therapy with undetectable viral load and normal CD4 counts
PHASE I STUDY ELIGIBILITY CRITERIA:\r\nHuman immunodeficiency virus (HIV)-positive patients on antiretroviral therapy are ineligible; however, patients with long-standing (> 5 years) HIV on antiretroviral therapy > 1 month (undetectable HIV viral load and CD4 count > 150 cells/uL) may be eligible if the PI determines no anticipated clinically significant drug-drug interactions
PHASE II STUDY COHORT 5 TRIPLE NEGATIVE BREAST CANCER ELIGIBILITY CRITERIA (MEDI+O ONLY):\r\nHIV-positive patients on anti-retroviral therapy are ineligible; however, patients with long-standing (> 5 years) HIV on antiretroviral therapy > 1 month (undetectable HIV viral load and CD4 count > 150 cells/uL) may be eligible if the PI determines no anticipated clinically significant drug-drug interactions
PHASE II STUDY METASTATIC CASTRATE-RESISTANT PROSTATE CANCER COHORT 4 ELIGIBILITY CRITERIA (MEDI+O ONLY):\r\nHIV-positive patients on combination antiretroviral therapy are ineligible; however, patients with long-standing (> 5 years) HIV on antiretroviral therapy > 1 month (undetectable HIV viral load and CD4 count > 150 cells/uL) may be eligible if the PI determines no anticipated clinically significant drug-drug interactions
PHASE II COLORECTAL CANCER COHORT 6 (MEDI+C ONLY):\r\nHIV-positive patients on anti-retroviral therapy are ineligible; however, patients with long-standing (> 5 years) HIV on antiretroviral therapy > 1 month (undetectable HIV viral load and CD4 count > 150 cells/?L) may be eligible if the PI determines no anticipated clinically significant drug-drug interactions
Stable, continuous antiretroviral treatment, defined as a multi-drug regimen (excluding zidovudine, also known as azidothymidine [AZT], Retrovir) prior to enrollment, as demonstrated by HIV plasma viral load < 50 copies/mL
Patients with a detectable human immunodeficiency virus (HIV) viral load or who are HIV-positive AND have a resistant genotype
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are eligible provided that they meet the following criteria in addition to the other protocol criteria: \r\n* Cancer as the only acquired immunodeficiency syndrome (AIDS)-defining condition\r\n* Cluster of differentiation (CD)4 cell count >= 250\r\n* Treatment sensitive HIV and prospects for long term survival on the basis of HIV disease alone\r\n* Willing to take anti-HIV therapy that will have minimal potential for pharmacokinetic interactions with GDC-0449
Human immunodeficiency virus (HIV) positive patients are allowed on this study if they have a CD4 count > 400, and are on a stable antiviral regimen; patients with poorly controlled HIV or other chronic active viral infections will be excluded
RANDOMIZED PHASE II (ARMS K AND L): HIV positive patients are eligible provided they meet the other protocol criteria including the following:\r\n* Long term survival expected were it not for the cHL\r\n* HIV viral loads undetectable by standard clinical HIV testing\r\n* Willing to adhere to effective combination antiretroviral therapy
For patients with HIV-associated KS:\r\n* Must be receiving, and adherent to, a highly active antiretroviral therapy (HAART) regimen consistent with current clinical guidelines\r\n* Must have been receiving HAART for at least one month\r\n* Must have achieved an HIV viral load (VL) < 10,000 copies/mL
Human immunodeficiency virus (HIV) positive (+) patients with CD4 counts >= 250 cells/mm^3 on anti-viral therapy are eligible for the study
Patients with known active human immunodeficiency virus (HIV) infection; patients with chronic HIV with a CD4 > 250, undetectable viral load by PCR, without opportunistic infection, and on a stable regimen of highly active anti-retroviral therapy (HAART) therapy would be eligible
Patients receiving antiretroviral therapy (highly active antiretroviral therapy [HAART]) for human immunodeficiency virus (HIV) infection are excluded from the study
Human immunodeficiency virus (HIV) infection, unless the patient is receiving effective antiretroviral therapy with undetectable viral load and normal CD4 counts
Patients known to be human immunodeficiency virus (HIV) positive must be stable and currently receiving antiretroviral therapy with a CD4 count > 400
Patients positive for human immunodeficiency virus (HIV) are allowed on study, but HIV-positive patients must have:\r\n* A stable regimen of highly active antiretroviral therapy (HAART)\r\n* No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections\r\n* A CD4 count above 250 cells/mcL and an undetectable HIV viral load on standard polymerase chain reaction (PCR) -based tests
Patients known to be human immunodeficiency virus (HIV) positive are eligible if they meet the following criteria within 4 weeks prior to randomization:\r\n* A stable regimen of highly active anti-retroviral therapy (HAART) and;\r\n* No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections; and\r\n* A CD4 count above 250 cells/mcL and an undetectable HIV viral load on standard PCR-based tests
REGISTRATION TO TREATMENT (STEP 1): Patients who are human immunodeficiency virus (HIV) positive are eligible if they have undetectable HIV viral load and CD4+ T-cell count >= 250/mm^3
REGISTRATION TO TREATMENT (STEP 2): Patients who are human immunodeficiency virus (HIV) positive are eligible if they have undetectable HIV viral load and CD4+ T-cell count >= 250/mm^3
For human immunodeficiency virus (HIV)+ patients: documented HIV-1 infection with CD4 count > 200 cells/mm^3 and viral load < 75 copies/mL, within 28 days of day 0.
Human immunodeficiency virus (HIV)-positive patients on highly active antiretroviral therapy (HAART) are excluded
Human immunodeficiency virus (HIV)-positive subjects positive for human immunodeficiency virus (HIV) are NOT excluded from this study, but HIV-positive subjects must have: \r\n* A stable regimen of highly active anti-retroviral therapy (HAART) \r\n* No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections\r\n* CD4 count above 250 cells/mcL and an undetectable HIV viral load on standard PCR-based test
Patients positive for human immunodeficiency virus (HIV) are NOT excluded from this study, but HIV-positive patients must have:\r\n* A stable regimen of highly active anti-retroviral therapy (HAART)\r\n* No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections\r\n* A CD4 count above 250 cells/mcL and an undetectable HIV viral load on standard PCR-based tests
Patients positive for human immunodeficiency virus (HIV) are not excluded from this study, but HIV-positive patients must have: \r\n* A stable regimen of highly active anti-retroviral therapy (HAART) that does not include strong or moderate CYP3A4 inducers or inhibitors\r\n* No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections \r\n* A CD4 count above 250 cells/mcL and an undetectable HIV viral load on standard polymerase chain reaction (PCR)-based test
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; HIV-positive patients not on antiviral therapy with undetectable viral loads and CD4 counts > 300, and after confirmation of eligibility after discussing with the study chair are eligible
Patients with a known history of human immunodeficiency virus (HIV) are eligible, if they meet all of the following conditions:\r\n* No history of HIV complications with the exception of cluster of differentiation (CD)4 count < 200 cells/mm^3\r\n* No antiretroviral therapy with overlapping toxicity such as myelosuppression\r\n* HIV viral loads below the limit of detection\r\n* No history of highly active antiretroviral therapy (HAART)-resistant HIV
Healthy human immunodeficiency virus (HIV)-infected patients are eligible, provided that they meet all the other study criteria in addition to the following (HIV testing is not required for study enrollment):\r\n* CD4+ cell count >= 250/mm^3\r\n* HIV viral loads undetectable by standard clinical tests
HIV plasma viral load < 50 copies/ml
Patients who are human immunodeficiency virus (HIV) positive may participate if they meet the following eligibility requirements:\r\n* They must be stable on their anti-retroviral regimen, and they must be healthy from an HIV perspective\r\n* They must have a cluster of differentiation (CD)4 count of greater than 250 cells/mcL\r\n* They must not be receiving prophylactic therapy for an opportunistic infection
Patients with human immunodeficiency virus (HIV) infection are not automatically excluded, but must meet the following criteria: cluster of differentiation (CD)4 count is > 499/cu mm and their viral load is < 50 copies/ml; use of highly active anti-retroviral therapy (HAART) is allowed
Patients with concurrent human immunodeficiency virus (HIV) infection may be enrolled if compliant with 3 or more drug anti-retroviral regimen and virus load less than 50 copies/ml and CD4 count greater than 250 cells/ml, and no concurrent opportunistic infection or other malignancy
HIV seropositive at or before the time of lymphoma diagnosis; all HIV positive patients are eligible regardless of HIV viral load or antiviral therapy (ART) status; all patients on study will receive ART as per standard guidelines
Patients who are known to be human immunodeficiency virus positive (HIV+) are eligible providing they meet all of the following additional criteria within 28 days prior to registration:\r\n* Cluster of differentiation (CD)4 cells >= 500/mm^3\r\n* Viral load of < 50 copies HIV messenger ribonucleic acid (mRNA)/mm^3 if on combination antiretroviral therapy (cART) or < 25,000 copies HIV mRNA if not on cART\r\n* No zidovudine or stavudine as part of cART\r\n* Patients who are HIV+ and do not meet all of these criteria are not eligible for this study
HIV-positive subjects with a CD4 count < 200 cells/?L are excluded due to the increased risk of lethal infections when treated with marrow-suppressive chemotherapy(87)\r\n* NOTE: subjects with HIV infection and a CD4 count >= 200 cells/?L are eligible but combination antiretroviral therapy should be held during administration of chemotherapy due to the potential for pharmacokinetic interactions with decita-bine, cytarabine or daunorubicin. Antiretroviral therapy may be resumed 24 hours after completion of the last dose of induction chemotherapy
Patients with human immunodeficiency virus (HIV) infection are eligible; patients with HIV infection must meet the following: no evidence of co-infection with hepatitis B or C; CD4+ count > 400/ul; no evidence of resistant strains of HIV; on anti-HIV therapy with an HIV viral load < 50 copies HIV RNA/mL; no history of acquired immunodeficiency syndrome (AIDS)-defining conditions; no zidovudine or stavudine are allowed owing to overlapping toxicity with chemotherapy
Patients with HIV disease are eligible for this study provided that:\r\n* Patients will be seen in the infectious disease (ID)/HIV clinic prior to enrollment on study for the purpose of determining eligibility and for local coordination of HIV care during the peri-transplant period\r\n* Must be on a maximally active anti-HIV regimen to control disease as determined appropriate by the ID/HIV physicians; for the majority of patients, this will be a highly active anti-retroviral therapy (HAART)-type therapy including a protease inhibitor\r\n* Cluster of differentiation (CD)4+ >= 50/uL\r\n* HIV ribonucleic acid (RNA) viral load =< 100,000 copies per mL on each of samples 4 weeks apart; the most recent level must be within one month of enrollment
Patients known to be human immunodeficiency virus (HIV) positive are eligible if they meet the following criteria within 30 days prior to registration: stable and adequate cluster of differentiation 4 (CD4) counts (>= 350 mm^3), and serum HIV viral load of < 25,000 IU/ml; patients may be on or off anti-viral therapy so long as they meet the CD4 count criteria
On an effective combination cART regimen, generally a 3-drug regimen based on Department of Health and Human Services (DHHS) treatment guidelines\r\n* Patients must be on cART >= 4 weeks; and\r\n* Evidence of viral suppression defined as HIV viral load < 200 copies/mL; and \r\n* No symptomatic AEs > grade 1 by Common Terminology Criteria for Adverse Events (CTCAE) criteria probably or definitely attributed to cART; and\r\n* No laboratory AEs noted on protocol defined screening laboratories > grade 1 by CTCAE criteria probably or definitely attributed to cART, with exceptions noted below\r\n* Note: if cART is modified during the screening period, patients must be on an effective new regimen for >= 2 weeks and otherwise meet eligibility criteria\r\n* Most patients have viral loads that are suppressible to < 50 copies/mL, but about 25% of patients will occasionally have blips up to 400â€“500 copies/mL, which do not appear to correlate with lack of viral suppression in most studies; thus, an HIV viral load of =< 400 copies/mL for an occasional â€œblipâ€ will be allowed, if there is documentation of an HIV viral load < 200 on the same regimen and no significant treatment interruption
Human immunodeficiency virus (HIV)-positive patients with well-controlled disease, as determined by CD4 count and viral load, who are on antiretroviral therapy that does not contain a strong inducer or inhibitor of CYP3A4 are allowed on trial; HIV-positive patients on combination antiretroviral therapy with strong inducers or inhibitors of CYP3A4 are ineligible; patients with poorly controlled HIV are not eligible
Patients with active human immunodeficiency virus (HIV) infection are eligible if their cluster of differentiation (CD)4 count is > 499/cu mm and their viral load is < 50 copies/ml; use of highly active antiretroviral treatment (HAART) is allowed
HIV positive patients on antiretroviral therapy regimen must be willing to suspend all highly active antiretroviral therapy (HAART) except in circumstances described
Patients who are known to be human immunodeficiency virus positive (HIV+) may be eligible providing they meet all of the following additional criteria:\r\n* Patients must have no history of acquired immunodeficiency syndrome (AIDS) defining events\r\n* Cluster of differentiation (CD)4 cells >= 500/mm^3\r\n* Viral load of < 50 copies HIV messenger ribonucleic acid (mRNA)/mm^3 if on combination antiretroviral therapy (cART) or < 25,000 copies HIV mRNA if not on cART\r\n* No zidovudine or stavudine as part of cART
No known HIV-positive or AIDS unless patient is on a stable highly active antiretroviral therapy (HAART) regimen, have CD4 (cluster of differentiation 4) counts >350, with no detectable viral load on quantitative polymerase chain reaction test
Patients who are known to be human immunodeficiency virus positive (HIV+) are eligible providing they meet all of the following additional criteria within 28 days prior to registration:\r\n* Cluster of differentiation (CD)4 cells >= 500/mm^3\r\n* Viral load of < 50 copies HIV messenger ribonucleic acid (mRNA)/mm^3 if on combination antiretroviral therapy (cART) or < 25,000 copies HIV mRNA if not on cART\r\n* No zidovudine or stavudine as part of cART\r\n* Patients who are HIV+ and do not meet all of these criteria are not eligible for this study
Patients with active infections including known human immunodeficiency virus (HIV) are not eligible; HIV positive patients on highly active anti-retroviral therapy (HAART) with undetectable blood HIV levels are eligible; patients with a history or serological evidence of exposure to hepatitis B without active infection are eligible for this study
Patients who are known to be human immunodeficiency virus (HIV) positive (+) may be eligible providing they meet all of the following additional criteria within 28 days prior to registration:\r\nâ€¢ CD4 cells >= 500/mm^3\r\nâ€¢ Viral load of < 50 copies HIV messenger ribonucleic acid (mRNA)/mm^3 if on combination antiretroviral therapy (cART) or < 25,000 copies HIV mRNA if not on cART\r\nâ€¢ No zidovudine or stavudine as part of cART\r\nPatients who are HIV+ and do not meet all of these criteria are not eligible for this study
Human immunodeficiency virus positive (HIV+) patients will be considered eligible if they are on highly active anti-retroviral therapy (HAART) and have a cluster of differentiation (CD)4 count of >= 200/ul (HIV+ patients who are on HAART and have a CD4 count < 200/ul are eligible if the plasma viral load is below the level of detection according to the local assay)
HIV+ patients who are not on HAART or have a CD4 count of < 200/ul in the presence of detectable plasma viral load according to the local assay
In order for patients with known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS) to be eligible, they must be on a stable highly active antiretroviral therapy (HAART) regimen, have cluster of differentiation (CD)4 counts > 350, with no detectable viral load on quantitative polymerase chain reaction (PCR)
Patients who are HIV positive with a detectable viral load > 750 copies/ml on adequate retroviral therapy must be evaluated for HIV drug resistance test (HIV-1 genotype); these patients may be enrolled only after discussion with the principal investigator (PI) and the infectious disease team
HIV-positive patients on combination antiretroviral therapy which include cytochrome p450 inhibitors are ineligible; patients with CD4 counts less than 300 CD4+ cells/mm^3 and or a high viral load are ineligible
Human immunodeficiency virus (HIV)-positive patients are not excluded but, to enroll, must meet all of the below criteria:\r\n* HIV is sensitive to antiretroviral therapy\r\n* Must be willing to take effective antiretroviral therapy, if indicated\r\n* Cluster of differentiation (CD)4 count at screening >= 300 cells/mm^3\r\n* No history of acquired immunodeficiency syndrome (AIDS)-defining conditions\r\n* If on antiretroviral therapy, must not be taking zidovudine or stavudine\r\n* Must be willing to take prophylaxis for pneumocystis jiroveci pneumonia (PCP) during therapy and until at least 2 months following the completion of therapy or until the CD4 cells recover to over 250 cells/mm^3, whichever occurs later
Human immunodeficiency virus (HIV)-patients positive for human immunodeficiency virus (HIV) are NOT excluded from this study, but HIV-positive patients must have: \r\n* A stable regimen of highly active anti-retroviral therapy (HAART) \r\n* No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections \r\n* A CD4 count above 250 cells/mcL and an undetectable HIV viral load on standard PCR-based test
Untreatable HIV infection due to multidrug ARV resistance. Subjects with a detectable or standard viral load > 750 copies/mL should be evaluated with an HIV drug resistance test (HIV-1 genotype). The results should be included as part of the ARV review (described in Appendix D).
Patients positive for human immunodeficiency virus (HIV) are NOT excluded from this study, but HIV-positive patients must have:\r\n* A stable regimen of highly active anti-retroviral therapy (HAART)\r\n* No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections\r\n* A CD4 count above 250 cells/mcL and an undetectable HIV viral load on standard PCR-based tests
Has uncontrolled human immunodeficiency virus (HIV) (defined as HIV RNA >500 copies/ml and CD4+ count<200/mmÂ³ on antiretroviral therapy)infection, or hepatitis B (defined as ALT > 1 x ULN, and HBV DNA >2000 IU/ml), or hepatitis C (defined as ALT > 1 x ULN, persistent viremia on antiviral therapy) infections.
For patients with unknown human immunodeficiency virus (HIV) status at the time of enrollment, HIV serology must be tested during screening; patients who are tested positive for HIV could be included if there is an adequate cluster of differentiation 4 (CD4) count (> 350/ul) on a stable regimen of highly active anti-retroviral therapy (HAART) with no detectable or minimal viral burden, and no active infections
If HIV+ positive, all patients infected with human immunodeficiency virus (HIV) may be eligible for study provided that their CD4+ count >= 300/uL; their viral load is undetectable; they are currently receiving highly active antiretroviral therapy (HAART)
Patient is human immunodeficiency virus (HIV) positive\r\nNote: patients who are human immunodeficiency virus (HIV) positive may participate IF they meet the following eligibility requirements:\r\n* They must be stable on their anti-retroviral regimen, and they must be healthy from an HIV perspective \r\n* They must have a cluster of differentiation (CD)4 count of greater than 250 cells/mcL\r\n* They must not be receiving prophylactic therapy for an opportunistic infection
Patients with human immunodeficiency virus (HIV) infection may be eligible provided they meet the following criteria:\r\n* CD4-positive cell count >= lower limit of institutional normal\r\n* HIV viral load < 10,000 copies HIV ribonucleic acid (RNA)/mL (if not on anti-HIV therapy) OR < 50 copies HIV RNA/mL (if on anti-HIV therapy)\r\n* No evidence of hepatitis B or C infection\r\n* No evidence of resistant strains of HIV\r\n* No history of acquired immune deficiency syndrome (AIDS)-defining condition
Patients with human immunodeficiency virus (HIV) infection are eligible provided they meet the following criteria: no evidence of co-infection with hepatitis B or C, cluster of differentiation (CD)4 count >= 400 cells/mm^3, no resistant viral strains, on highly active antiretroviral treatment (HAART) therapy with a viral load < 50 RNA copies/ml, and no history of acquired immunodeficiency syndrome (AIDS)-defining conditions
Individuals with a known history of human immunodeficiency virus (HIV) positivity may be included in the study as long as they are on appropriate highly active anti-retroviral therapy (HAART) therapy
Patients must not have human immunodeficiency virus (HIV) or be taking highly active antiretroviral therapy (HAART) therapy
Patients with human immunodeficiency virus (HIV) infection are eligible; patients with HIV infection must meet the following: no evidence of co-infection with hepatitis B or C; cluster of differentiation (CD)4+ count >= 400/mm; no evidence of resistant strains of HIV; on anti-HIV therapy with an HIV viral load < 50 copies HIV ribonucleic acid (RNA)/mL; no history of acquired immune deficiency syndrome (AIDS) defining conditions
Positive test for the human immunodeficiency virus (HIV), unless undetectable viral load within 3 months of enrollment (HIV ribonucleic acid [RNA] less than 48 copies/mL) on highly active antiretroviral therapy (HAART) therapy
Untreatable HIV infection due to multidrug antiretroviral resistance. Patients with a detectable viral load > 750 copies/ml should be evaluated with an HIV drug resistance test (HIV-1 genotype). The results should be included as part of the Antiretroviral Review (described in Appendix D). This Review Committee will make the final determination as to whether HIV viremia could potentially be suppressed with alternate antiretroviral therapy. .
Patients with human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS) are allowed on study if they have an undetectable viral load, cluster of differentiation (CD)4 > 300 and on stable highly active antiretroviral therapy (HAART) regimen for 1 month
Patients positive for human immunodeficiency virus (HIV) are allowed on study, but HIV-positive patients must have:\r\n* A stable regimen of highly active anti-retroviral therapy (HAART) using combination retroviral agents which are not CYP3A4 inducers or inhibitors\r\n* No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections\r\n* A CD4 count above 250 cells/mcL and an undetectable HIV viral load on standard polymerase chain reaction (PCR)-based tests
Patients known to be positive for human immunodeficiency virus (HIV) are NOT excluded from this study, but HIV-positive patients must have: \r\n* A stable regimen of highly active anti-retroviral therapy (HAART) \r\n* No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections \r\n* A CD4 count above 250 cells/mcL and an undetectable HIV viral load on standard PCR-based test\r\n* HIV testing is not required
Patients with human immunodeficiency virus (HIV) infection must be willing to comply with a regimen of highly active antiretroviral therapy (HAART)
Patients with human immunodeficiency virus (HIV) infection are not automatically excluded, but must meet the following criteria: cluster of differentiation 4 (CD4) count is > 499/cu mm and their viral load is < 50 copies/ml; use of highly active antiretroviral therapy (HAART) is allowed
All participants must be on antiretroviral therapy for HIV infection with CD4 count > 50/mm^3 and viral load < 50 copies/mL; participants must be on a stable antiretroviral therapy (ART) regimen that includes at least three agents, as defined below\r\n* If antiretroviral regimen contains zidovudine or strong cytochrome P450, family 3, subfamily A, polypeptide 4 (Cyp3A4) inhibitors (e.g. ritonavir or cobicistat-boosted protease inhibitors) and viral load is suppressed (as measured by HIV viral load =< 50/mL), then antiretroviral therapy must be adjusted to a less toxic therapy not containing these antivirals and must demonstrate stability for at least 4 weeks prior to enrollment\r\n* If on antiviral therapy with zidovudine or protease inhibitors, and viral load is not suppressed (as measured by HIV viral load > 50 copies/mL), then antiretroviral therapy must be adjusted to a less toxic regimen allowing for optimal viral suppression and must demonstrate stability for at least 12 weeks prior to enrollment\r\n* Allowable antiretrovirals include nucleoside or nucleotide inhibitors other than zidovudine, non-nucleoside reverse transcriptase inhibitors including efavirenz, etravirine, rilpivirine, and nevirapine, integrase inhibitors raltegravir or dolutegravir, or entry inhibitors maraviroc or enfuvirtide
Human immunodeficiency virus (HIV)-positive diagnosis with a CD4 count of less than 100 mm3 or detectable viral load within past 3 months and receiving anti-retroviral therapy.
Human immunodeficiency virus (HIV)-positive patients are eligible if on stable dose of highly active antiretroviral therapy (HAART), cluster of differentiation (CD)4 counts are greater than 350 and viral load is undetectable
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are eligible if they have been on antiretrovirals (ARVs) for >= 6 months and undetectable viral loads
Patients who are human immunodeficiency virus (HIV) positive may participate IF they meet the following eligibility requirements:\r\n* They must be stable on their anti-retroviral regimen, and they must be healthy from an HIV perspective \r\n* They must have a CD4 count of greater than 250 cells/mcL\r\n* They must not be receiving prophylactic therapy for an opportunistic infection
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are eligible, unless the patientâ€™s CD4 count is below the institutional lower limit of normal, or the patient is taking prohibited CYP3A4/5 strong inhibitors or inducers
Patients with human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS) are allowed on study if they have an undetectable viral load, cluster of differentiation (CD)4 > 300 and are on a stable highly active antiretroviral therapy (HAART) regimen for 1 month prior to study enrollment
Human immunodeficiency virus (HIV) infection, unless the patient is receiving effective antiretroviral therapy with undetectable viral load and normal CD4 counts
Patients who are known to be human immunodeficiency virus (HIV) positive (+) are eligible providing they meet all of the following additional criteria within 28 days prior to registration:\r\n* Cluster of differentiation (CD) 4 cells >= 500/mm^3\r\n* Viral load < 50 copies of HIV messenger ribonucleic acid (mRNA)/mm^3 if on combination antiretroviral therapy (cART) or < 25,000 copies of HIV mRNA if not on cART\r\n* No zidovudine or stavudine as part of cART; patients who are HIV+ and do not meet all of these criteria are not eligible for this study
Acute active (such as tuberculosis or malaria), serious, uncontrolled infection; participants with a CD4 count =< 50/mm^3 (0.05 x 10^9/L) will be excluded if they have had an opportunistic infection within the past 3 months, or if there is evidence of resistance to antiretroviral therapy (i.e., HIV viral load >= 400 copies/mL despite combination antiretroviral therapy for at least 4 months)
Viral load has decreased by >= 1.5 logs or viral load < 5000 copies/ml plasma on HAART therapy
Human immunodeficiency virus (HIV) infection, unless receiving effective antiretroviral therapy with undetectable viral load and normal CD4 counts
Patients who are human immunodeficiency virus (HIV) positive may participate IF they meet the following eligibility requirements:\r\n* They must be stable on their anti-retroviral regimen, and they must be healthy from an HIV perspective \r\n* They must have a CD4 count of greater than 250 cells/mcL\r\n* They must not be receiving prophylactic therapy for an opportunistic infection\r\n* Must be on antiretroviral therapy and there must be minimal interactions or overlapping toxicity of the antiretroviral therapy with the experimental cancer treatment\r\n* HIV viral load must be < 200 copies/ mm^3 by standard clinical assays
Human immunodeficiency virus (HIV)+ positive patients are eligible if their CD4+ count >= 300/uL and they have an undetectable viral load; in addition, they must be currently receiving highly active antiretroviral therapy (HAART) and be under the care of an infectious diseases specialist
Patients with a known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS) will be eligible if:\r\n* They are generally healthy from an HIV perspective and on a stable anti-retroviral regimen for > 6 months\r\n* They have had no AIDS-defining conditions in the past 12 months other than historically low CD4+ cell counts\r\n* They have an undetectable viral load on standard assays
Human immunodeficiency virus (HIV)-positive patients are ineligible; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated
Patients on antiretroviral therapy.
Human immunodeficiency virus (HIV)-positive participants on combination antiretroviral therapy are ineligible; appropriate studies will be undertaken in participants receiving combination antiretroviral therapy when indicated
Known human immunodeficiency virus (HIV)-positive participants; appropriate studies will be undertaken in participants receiving combination antiretroviral therapy when indicated
Patients should be excluded if they have known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS); appropriate studies will be undertaken in participants receiving combination antiretroviral therapy when indicated
Human immunodeficiency virus (HIV)-positive participants on combination antiretroviral therapy are ineligible; appropriate studies will be undertaken in participants receiving combination antiretroviral therapy when indicated
Participants known to be human immunodeficiency virus (HIV)-positive on combination antiretroviral therapy are ineligible; appropriate studies will be undertaken in participants receiving combination antiretroviral therapy when indicated; screening for HIV infection at baseline is not required
Medical history:\r\n* History of intracranial abscess within 6 months prior to start of study therapy\r\n* Known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS)\r\n* NOTE: HIV-positive participants on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with nivolumab\r\n* Appropriate studies will be undertaken in participants receiving combination antiretroviral therapy when indicated\r\n* History of allergy to study drug components\r\n* History of severe hypersensitivity reaction to any monoclonal antibody;
Known human immunodeficiency virus (HIV)-positive participants on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with prexasertib and LY3300054. In addition, these participants are at increased risk of lethal infections when treated with marrow-suppressive therapy such as prexasertib.
Participants with a known history of human immunodeficiency virus (HIV) are ineligible; appropriate studies will be undertaken in participants receiving combination antiretroviral therapy when indicated
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated
Known human immunodeficiency virus (HIV)-positive participants; HIV-positive patients on combination antiretroviral therapy are ineligible; appropriate studies will be undertaken in participants receiving combination antiretroviral therapy when indicated
Known human immunodeficiency virus (HIV)-positive participants are ineligible; appropriate studies will be undertaken in participants receiving combination antiretroviral therapy when indicated
Known human immunodeficiency virus (HIV)-positive participants are ineligible; appropriate studies will be undertaken in HIV-positive participants when indicated.
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated
Known to be human immunodeficiency virus (HIV)-positive on combination antiretroviral therapy; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated
Human immunodeficiency virus (HIV)-positive participants on combination antiretroviral therapy are ineligible; appropriate studies will be undertaken in participants receiving combination antiretroviral therapy when indicated
Human immunodeficiency virus (HIV)-positive patients receiving combination anti-retroviral therapy are excluded from the study; appropriate studies will be undertaken in patients receiving combination anti-retroviral therapy when indicated; note: HIV testing is not required for entry into this protocol
Known human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with chemotherapeutic drugs. In addition, these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy.
Human immunodeficiency virus (HIV)-positive participants on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with study drug. In addition, these participants are at increased risk of lethal infections when treated with marrow-suppressive therapy
Known human immunodeficiency virus (HIV)-positivity on combination antiretroviral therapy; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated
Human immunodeficiency virus (HIV)-positive patients receiving combination anti-retroviral therapy are excluded from the study; appropriate studies will be undertaken in patients receiving combination anti-retroviral therapy when indicated; Note: HIV testing is not required for entry into this protocol
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with apalutamide and abiraterone. Appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated.
Patients known to be human immunodeficiency virus (HIV)-positive patients and on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with the study drugs. In addition, these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy. Appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated.
Patients who are known human immunodeficiency virus (HIV), hepatitis B or hepatitis C positive; HIV-positive patients on combination antiretroviral therapy are ineligible; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated; HIV, hepatitis B and hepatitis C testing is not required for patients not known to have those infections
Participants known to be human immunodeficiency virus (HIV)-positive and on combination antiretroviral therapy are ineligible; appropriate studies will be undertaken in participants receiving combination antiretroviral therapy when indicated
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated
Patients are excluded if they have known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS); appropriate studies will be undertaken in participants receiving combination antiretroviral therapy when indicated
Known human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infection (with the exception of chronic or cleared HBV and HCV infection, which will be allowed)\r\n* HIV-positive patients on combination antiretroviral therapy are ineligible; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated
Human immunodeficiency virus (HIV) infection: HIV-positive patients on combination antiretroviral therapy are ineligible; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated
Known history of human immunodeficiency virus (HIV) infection (testing not mandatory); NOTE: HIV-positive subjects on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with ribociclib; in addition, these subjects are at increased risk of lethal infections when treated with marrow suppressive therapy; appropriate studies will be undertaken in subjects receiving combination antiretroviral therapy when indicated
Known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS); HIV-positive patients on combination antiretroviral therapy are ineligible; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated
Known human immunodeficiency virus (HIV) infection\r\n* HIV-positive patients are at increased risk of lethal infections when treated with marrow suppressive therapy; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated
Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness (HIV-positive subjects on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with oral THU-Dec; appropriate studies will be undertaken in subjects receiving combination antiretroviral therapy when indicated
Subjects who are human immunodeficiency virus (HIV)-positive will be excluded from the study\r\n* Appropriate studies will be undertaken in subjects receiving combination antiretroviral therapy when indicated; also include whether HIV testing is required for this study, or only if a known diagnosis will be excluded
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; in addition, these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated
Human immunodeficiency virus (HIV) positive (+) with a cluster of differentiation (CD)4 count < 200 are ineligible; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated
Known human immunodeficiency virus (HIV)-positivity on combination antiretroviral therapy; in addition, these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated
Known human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; in addition, these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy
Known human immunodeficiency virus (HIV)-positivity on combination antiretroviral therapy; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated
Known HIV-positivity on combination antiretroviral therapy because of the unknown potential for pharmacokinetic interactions with indoximod, or docetaxel. In addition, these patients are at increased risk of lethal infections when treated with marrow suppressive therapy.
Human immunodeficiency (HIV)-positive individuals on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with STA-9090; in addition, these individuals are at increased risk of lethal infections when treated with marrow-suppressive therapy; appropriate studies will be undertaken in participants receiving combination antiretroviral therapy when indicated
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with copanlisib or nivolumab\r\n* Patients with human immunodeficiency virus (HIV): HIV-positive patients on combination antiretroviral therapy are ineligible; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated; patients with evidence of hepatitis B virus (HBV) are eligible provided there is minimal hepatic injury and the patient has undetectable HBV on suppressive HBV therapy; patient must be willing to maintain adherence to HBV therapy\r\n* Patients with previously treated and eradicated hepatitis C virus (HCV) who have minimal hepatic injury are eligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with AMG 232; in addition, these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated
PHASE II: HIV-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with veliparib; in addition, these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated
Patients with known human immunodeficiency virus (HIV) are excluded; appropriate studies may be undertaken in patients with HIV and those receiving combination anti-retroviral therapy in the future
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated
Human immunodeficiency virus (HIV)-positive patients receiving combination anti-retroviral therapy are excluded from the study; appropriate studies will be undertaken in patients receiving combination anti-retroviral therapy when indicated
Human immunodeficiency virus (HIV)-positive subjects on combination antiretroviral therapy are ineligible; appropriate studies will be undertaken in subjects receiving combination antiretroviral therapy when indicated; HIV testing prior to enrollment is not required for screening but strongly encouraged for patients with no documented prior HIV assessment
Because patients with immune deficiency are at increased risk of lethal infections when treated with bone marrow suppressive therapy, human immunodeficiency virus (HIV)-positive patients are excluded from the study; for patients receiving combination antiretroviral therapy, the potential impact of pharmacokinetic interactions with HCQ and VEM is unknown; appropriate studies may be undertaken in patients with HIV and those receiving combination anti-retroviral therapy in the future
Known HIV positivity on combination antiretroviral therapy; these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated
Patient must not be known to be human immunodeficiency virus (HIV)-positive on combination antiretroviral; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated
HIV-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with mFOLFIRINOX. In addition, these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy. Appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated.
Known HIV-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with bevacizumab. In addition, these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy. Appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated.
Known human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with vorinostat; in addition, these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; HIV-positive patients with cluster of differentiation (CD)4+ =< 500/mm^3 are ineligible; appropriate studies will be undertaken in this group of patients when indicated
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with tretinoin; in addition, these patients are at increased risk of lethal infections when treated with marrow suppressive therapy; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy known to interact with CYP isoenzymes are ineligible; in addition, HIV patients with CD4 count < 200 cells/uL are ineligible; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated
Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness (HIV-positive subjects on combination antiretroviral therapy are ineligible; appropriate studies will be undertaken in subjects receiving combination antiretroviral therapy when indicated
Patient must not be known to be human immunodeficiency virus (HIV)-positive on combination antiretroviral; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with erlotinib; in addition, these patients are at increased risk of lethal infections; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated
Human Immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated
Human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are ineligible; appropriate studies will be undertaken in participants receiving combination antiretroviral therapy when indicated
Patients with known human immunodeficiency virus (HIV) are ineligible; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with zolpidem; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated
Known human immunodeficiency virus (HIV)-positive patients on combination anti-retroviral therapy are ineligible; appropriate studies will be undertaken in patients receiving combination anti-retroviral therapy when indicated
Known human immunodeficiency virus (HIV)-positivity on combination antiretroviral therapy
Known human immunodeficiency virus (HIV)-positivity on combination antiretroviral therapy
Known human immunodeficiency virus (HIV)-positivity on combination antiretroviral therapy
Known human immunodeficiency virus (HIV)-positivity on combination antiretroviral therapy
Known human immunodeficiency virus (HIV)-positivity and on combination antiretroviral therapy
Known human immunodeficiency virus (HIV)-positivity AND actively being treated with highly active antiretroviral therapy (HAART)
Known human immunodeficiency virus (HIV)-positivity on combination antiretroviral therapy
Know human immunodeficiency virus (HIV) positivity on combination antiretroviral therapy
Known human immunodeficiency virus (HIV)-positivity on combination antiretroviral therapy
Known human immunodeficiency virus (HIV)-positivity and on combination antiretroviral therapy
Known human immunodeficiency virus (HIV)-positivity on combination antiretroviral therapy
Subject has known Human Immunodeficiency Virus (HIV) positivity (subjects who are receiving antiretroviral therapy for HIV disease).
Phase I and Arm 1 of Phase II: Known human immunodeficiency virus (HIV)-positivity and on combination antiretroviral therapy; Arms 2 and 3 of Phase II: patients with HIV infection and antiretroviral therapy are not excluded
Known human immunodeficiency virus (HIV)-positivity and on combination antiretroviral therapy
Known human immunodeficiency virus (HIV)-positivity on combination antiretroviral therapy
Known human immunodeficiency virus (HIV)-positivity on combination antiretroviral therapy
Known human immunodeficiency virus (HIV)-positivity on combination antiretroviral therapy
Known human immunodeficiency virus (HIV)-positivity on combination antiretroviral therapy
Known human immunodeficiency virus (HIV)-positivity on combination antiretroviral therapy
Known human immunodeficiency virus (HIV)-positivity on combination antiretroviral therapy
Known human immunodeficiency virus (HIV)-positivity on combination antiretroviral therapy
Known human immunodeficiency virus (HIV)-positivity on combination antiretroviral therapy
Known human immunodeficiency virus (HIV)-positivity and on combination antiretroviral therapy
